A Chinese biosimilar maker valued at $1.5 billion might be the first to list its stock on Hong Kong’s exchange under new rules allowing startups and biotechs to go public. The company, called Shanghai Henlius Biotech, could do an IPO raising $500 million …
( read original story …)